Production (Stage)
Brainstorm Cell Therapeutics Inc.
BCLI
$1.24
$0.1412.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.31M | 7.04M | 8.68M | 9.38M | 9.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.31M | 11.69M | 13.31M | 16.30M | 18.76M |
| Operating Income | -12.31M | -11.69M | -13.31M | -16.30M | -18.76M |
| Income Before Tax | -11.09M | -11.62M | -14.23M | -12.75M | -15.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.09 | -11.62 | -14.23 | -12.75 | -15.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.09M | -11.62M | -14.23M | -12.75M | -15.53M |
| EBIT | -12.31M | -11.69M | -13.31M | -16.30M | -18.76M |
| EBITDA | -12.08M | -11.45M | -13.06M | -16.04M | -18.50M |
| EPS Basic | -2.02 | -2.35 | -3.46 | -3.36 | -4.84 |
| Normalized Basic EPS | -1.26 | -1.47 | -2.16 | -2.10 | -3.03 |
| EPS Diluted | -2.02 | -2.35 | -3.46 | -3.36 | -4.84 |
| Normalized Diluted EPS | -1.26 | -1.47 | -2.16 | -2.10 | -3.03 |
| Average Basic Shares Outstanding | 22.11M | 20.08M | 17.81M | 15.45M | 13.35M |
| Average Diluted Shares Outstanding | 22.11M | 20.08M | 17.81M | 15.45M | 13.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |